Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors

Abstract excerpt

// Adam Albitar 1 , Wanlong Ma 1 , Ivan DeDios 1 , Jeffrey Estella 1 , Inhye Ahn 2 , Mohammed Farooqui 3 , Adrian Wiestner 3 , Maher Albitar 1 1 NeoGenomics Laboratories, Irvine, CA, USA 2 Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA 3 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA Correspondence to: Maher Albitar, email: malbitar@neogenomics.com...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Immunodeficiency and Autoimmune Disorders
• Share to Lymphoma Diagnosis and Treatment